Skip to main content
SpringerLink
Log in

Mechanistic Concepts in Androgen-dependence of Prostate Cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Androgen blockade is the mainstay of therapy in the clinical management of advanced prostate cancer. Recent progress on two fronts – the development of newer xenograft and transgenic models and a greater understanding of nuclear receptor signaling – has provided new insight into mechanisms of androgen-dependence in prostate cancer. This review centers on the concept that perturbations in androgen receptor signaling are likely to occur early in prostate cancer and play a critical role in progression to end stage hormone-refractory disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ross RK, Pike MC, Coetzee GA, et al.: Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497-4504, 1998

    PubMed  Google Scholar 

  2. Ross RK, Schoffenfeld D: Prostate Cancer. In: Schottenfeld D, Fraumeni F Jr.: Cancer Epidemiology and Prevention, Oxford University Press, New York, 1998, p 1180

    Google Scholar 

  3. English HF, Kyprianou N, Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233-250, 1989

    PubMed  Google Scholar 

  4. Colombel MC, Buttyan R: Hormonal control of apoptosis: the rat prostate gland as a model system. Meth Cell Biol 46: 369-385, 1995

    Google Scholar 

  5. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988

    PubMed  Google Scholar 

  6. Kinbara H, Cunha GR, Boutin E, Hayashi N, Kawamura J: Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate 29: 107-116, 1996

    PubMed  Google Scholar 

  7. Cunha G: Growth factors as mediators of androgen action during male urogenital development. Prostate Supplement 22-25, 1996

  8. Hayward SW, Rosen MA, Cunha GR: Stromal-epithelial interactions in the normal and neoplastic prostate. Brit J Urol 79Supplement 2: 18-26, 1997

    PubMed  Google Scholar 

  9. Culig Z, Hobisch A, Cronauer MV, et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392-405, 1996

    Article  PubMed  Google Scholar 

  10. Westin P, Stattin P, Damber JE, Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146(6): 1368-1375, 1995

    PubMed  Google Scholar 

  11. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM: Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57: 4687-4691, 1997

    PubMed  Google Scholar 

  12. Quarmby VE, Beckman WC Jr, Cooke DB, et al.: Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 50: 735-739, 1990

    PubMed  Google Scholar 

  13. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor expression in human prostate carcinoma cell lines. Cancer Res 50: 5382-5386, 1990

    PubMed  Google Scholar 

  14. Trapman J, Ris-Stalpers C, van der Korput JAGM, et al.: The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Molec Biol 37: 837-842, 1990

    Article  PubMed  Google Scholar 

  15. Culig Z, Klocker H, Eberle J, et al.: DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22: 11-22, 1993

    PubMed  Google Scholar 

  16. Culig Z, Hobisch A, Hittmair A, et al.: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35: 63-70, 1998

    Article  PubMed  Google Scholar 

  17. van derKwast TH, Schalken J, Ruizeveld deWinter JA, et al.: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Intl J Cancer 48: 189-193, 1991

    Google Scholar 

  18. DeWinter JA, Trapman J, Brinkmann AO, et al.: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Path 161: 329-332, 1990

    Google Scholar 

  19. Koivisto P, Kononen J, Palmberg C, et al.: Androgen receptor gene amplification: a possible mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319, 1997

    PubMed  Google Scholar 

  20. Newmark JR, Hardy DO, Tonb DC, et al.: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci 89: 6319-6323, 1992

    PubMed  Google Scholar 

  21. Culig Z, Hobisch A, Cronauer MV, et al.: Mutant androgen receptor detected in advanced stage of prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541-1550, 1993

    Article  PubMed  Google Scholar 

  22. Elo JP, Kvist L, Leinonen K, et al.: Mutated human androgen receptor gene detected in a prostate cancer patient is also activated by estradiol. J Clin Endo Metab 80: 3494-3500, 1995

    Article  Google Scholar 

  23. Evans BAJ, Harper ME, Daniells CE, et al.: Low incidence of androgen receptor gene mutations in human prostatic tumors using single strandconformation polymorphism analysis. Prostate 28: 162-171, 1996

    Article  PubMed  Google Scholar 

  24. Veldscholte J, Berrevoets CA, Ris-Staipers C, et al.: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Molec Biol 41: 665-669, 1992

    Article  PubMed  Google Scholar 

  25. Culig Z, Hobisch A, Cronauer MV, et al.: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994

    PubMed  Google Scholar 

  26. Nazareth LV, Weigel NL: Activation of the human androgen receptor through a protein kinase A signalling pathway. J Biol Chem 271: 19900-19907, 1996

    Article  PubMed  Google Scholar 

  27. Hobisch A, Eder IE, Putz T, et al.: Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58: 4640-4645, 1998

    PubMed  Google Scholar 

  28. Chan JM, Stampfer MJ, Giovannucci E, et al.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998

    Article  PubMed  Google Scholar 

  29. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, Lee C: Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 77: 855-61, 1998

    PubMed  Google Scholar 

  30. Sherwood ER, Lee C: Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 13: 290-6, 1995

    Article  PubMed  Google Scholar 

  31. Glynne-Jones E, Goddard L, Harper ME: Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 27: 688-94, 1996

    Article  PubMed  Google Scholar 

  32. Connolly JM, Rose DP: Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24: 167-75, 1994

    PubMed  Google Scholar 

  33. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE: Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 15: 1115-20, 1997

    Article  PubMed  Google Scholar 

  34. McGarvey TW, Stearns ME: Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 63: 52-62, 1995

    Article  PubMed  Google Scholar 

  35. Culig Z, Hobisch A, Cronauer MV, et al.: Regulation of prostatic growth and function by peptide growth factors. Prostate 28: 392-405, 1996

    Article  PubMed  Google Scholar 

  36. Klein KA, Reiter RE, Redula J, et al.: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3: 402-408, 1997

    Article  PubMed  Google Scholar 

  37. Mellon K, Thompson S, Chariton RG, et al.: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urology 147: 496-499, 1992

    Google Scholar 

  38. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erb-B-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urology 150: 1427-1433, 1993

    Google Scholar 

  39. Sadasivan R, Morgan R, Jennings S, et al.: Overexpression of HER-2/Neu may be an indicator of poor prognosis in prostate cancer. J Urology 150: 126-131, 1993

    Google Scholar 

  40. Ross JS, Sheehan C, Hayner-Buchan AM, et al.: HER-2/neu gene amplification status in prostate cancer by fluorescence in situhybridization. Hum Pathol 28: 827-833, 1997

    Article  PubMed  Google Scholar 

  41. Ross JS, Sheehan CE, Hayner-Buchan AM, et al.: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situhybridization of prostate carcinoma. Cancer 79: 2162-2170, 1997

    Article  PubMed  Google Scholar 

  42. Arai Y, Tatsuhiro T, Yoshida O: c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30: 195-201, 1997

    Article  PubMed  Google Scholar 

  43. Hockenbery DM, Zuffer M, Hickey W, Nahm M, Korsmeyer S: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991

    PubMed  Google Scholar 

  44. McDonnell TJ, Troncoso P, Brisbay SM, et al.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992

    PubMed  Google Scholar 

  45. Colombel M, Symmans F, Gil S, et al.: Detection of apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 143: 390-400, 1993

    PubMed  Google Scholar 

  46. Liu AY, Corey E, Bladou F, Lange PH, Vessella RL: Prostatic cell lineage markers: emergence of BCL2C cells of human prostate cancer xenograft LuCaP 23 following castration. Intl J Cancer 65: 85-89, 1996

    Google Scholar 

  47. Raffo AJ, Penman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitroand confers resistance to androgen depletion in vivo. Cancer Res 55: 4438-4445, 1995

    PubMed  Google Scholar 

  48. Srikanth S, Kraft AS: Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 58: 834-839, 1998

    PubMed  Google Scholar 

  49. Anzick SL, Kononen J, Walker RL, et al.: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968, 1997

    Article  PubMed  Google Scholar 

  50. Yeh S, Chang C: Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93(11): 5517-5521, 1996

    Article  PubMed  Google Scholar 

  51. Miyamoto H, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU14S cells. Proc Natl Acad Sci USA 95(13): 7379-7384, 1998

    Article  PubMed  Google Scholar 

  52. Lavinsky RM, Jepsen K, Heinzel T, et al.: Diverse signalling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925, 1998 Note added in proof: The data showing effects of Her-2/neu on androgen receptor signaling is now published: Craft N, Shostak Y, Carey M, Sawyers C: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase Nature Medicine, 1999.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, USA

    Noah Craft & Charles L. Sawyers

Authors
  1. Noah Craft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles L. Sawyers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craft, N., Sawyers, C.L. Mechanistic Concepts in Androgen-dependence of Prostate Cancer. Cancer Metastasis Rev 17, 421–427 (1998). https://doi.org/10.1023/A:1006141806801

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006141806801

Search

Navigation